Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02835833
Title Study of Nintedanib Plus Bevacizumab in Advanced Solid Tumors
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors University of Alabama at Birmingham
Indications

lung non-small cell carcinoma

ovarian carcinoma

renal cell carcinoma

colorectal adenocarcinoma

cervix carcinoma

Therapies

Bevacizumab + Nintedanib

Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.